Abstract
Malignant hyperthermia (MH) in humans is usually triggered by volatile anaesthetics and depolarizing muscle relaxants. However, other factors or drugs (e.g. cresol) are thought to induce MH. We report a case of fulminant MH associated with a ketoacidotic diabetic coma. After therapy for diabetic coma with insulin (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and lost consciousness. MH was treated immediately with dantrolene; the patient recovered within 14 days. Five months later the patient was diagnosed as MH-susceptible by the in vitro caffeine and halothane contracture test. This case supports the assessment that MH and diabetes are associated diseases and that cresol could possibly trigger MH. Furthermore, therapy with dantrolene has been demonstrated to the beneficial in the treatment of MH associated with diabetic coma.
This is a preview of subscription content, log in via an institution to check access.
References
Gronert GA, Antognini JF (1994) Malignant hyperthermia. In: Miller RD (ed) Anesthesia, 4th edn. Churchill Livingstone, New York Edinburgh London, pp 1075–1093
Hackl W, Winkler M, Mauritz W, Sporn P, Steinbereithner K (1991) Muscle biopsy for diagnosis of malignant hyperthermia susceptibility in two patients with severe exercise-induced myolysis. Br J Anaesth 66:138–140
Wingard DW (1980) A stressful situation. Anesth Analg 59:321–322
Møller-Petersen J, Thorgaard Andersen P, Hjørne N, Ditzel J (1986) Nontraumatic rhabdomyolysis during diabetic ketoacidosis. Diabetologia 29:229–234
Wood MLB, Griffith DNW, Hooper RJL, Patterson DLH, Yudkin JS (1988) Fatal rhabdomyolysis associated with hyperosmolar diabetic decompensation. Diabetes Res 8:97–99
Smith RJ (1988) Preoperative assessment of risk factors. Br J Anaesth 60:317–319
Wappler F, Roewer N, Köchling A, Scholz J, Steinfath M, Schulte am Esch J (1996) In vitro diagnosis of malignant hyperthermia susceptibility with ryanodine-induced contractures in human skeletal muscles. Anesth Analg 82:1230–1236
Galloway GJ, Denborough MA (1986) Suxamethonium chloride and malignant hyperpyrexia. Br J Anaesth 58:447–450
Zorzato F, Scutari E, Tegazzin V, Clementi E, Treves S (1993) Chlorocresol: an activator of ryanodine receptor-mediated Ca2+ release. Mol Pharmacol 44:1192–1201
Herrmann-Frank A, Richter M, Sarközi S, Mohr U, Lehmann-Horn F (1996) 4-Chloro-m-cresol, a potent and specific activator of the skeletal muscle ryanodine receptor. Biochim Biophys Acta 1289:31–40
Campbell IT, Ellis FR, Evans RT (1981) Metabolic rate and blood hormone and metabolite levels of individuals susceptible to malignant hyperpyrexia at rest and in response to food and mild exercise. Anesthesiology 55:46–52
Campbell IT, Ellis FR, Evans RT, Mortimer MG (1983) Studies of body temperature, blood lactate, cortisol and free fatty acid levels during exercise in human subjects susceptible to malignant hyperpyrexia. Acta Anaesthesiol Scand 27:349–355
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wappler, F., Roewer, N., Köchling, A. et al. Fulminant malignant hyperthermia associated with ketoacidotic diabetic coma. Intensive Care Med 22, 809–812 (1996). https://doi.org/10.1007/BF01709525
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01709525